Mid infrared light treatment attenuates cognitive decline and alters the gut microbiota community in APP/PS1 mouse model.
Biochem Biophys Res Commun
; 523(1): 60-65, 2020 02 26.
Article
em En
| MEDLINE
| ID: mdl-31831179
ABSTRACT
Alzheimer's disease (AD) as the first most neurodegenerative disease in the elderly still has no effective therapy, suggesting that the intervention toolbox for AD should be expanded. One newly developed strategy involves the use of photobiomodulation, such as near infrared or far infrared light, which has proven to attenuate AD-associated pathology. However, the efficacy of mid infrared light (MIR) in treating AD is under investigated. With this in mind, we assessed the benefits of MIR light of peak wavelength 7.7-10 µm treatment on APP/PS1 transgenic mice. We found that APP/PS1 mice treated with MIR light had improved learning and memory abilities and reduced amyloid-ß (Aß) plaque load in the brain. We also surprisingly found that the gut microbiota composition in APP/PS1 mice treated with MIR light returned to normal (wild type mice) levels. Together, these findings suggested a novel non-invasive and promising avenue for AD treatment via photobiomodulation, and also proposed that future target for AD might be the gut microbiota via the brain-gut-skin axis.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Precursor de Proteína beta-Amiloide
/
Modelos Animais de Doenças
/
Presenilina-1
/
Doença de Alzheimer
/
Disfunção Cognitiva
/
Microbioma Gastrointestinal
/
Raios Infravermelhos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Biochem Biophys Res Commun
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
China